DXR - NASDAQ
Daxor Corporation
$11.09
+3.3%Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
At a Glance
Live Snapshotdxr
Common Stock
Last Annual Value
55.35K
3-Year CAGR
1%
5-Year CAGR
1%
10-Year CAGR
-41%
Daxor Corporation Competitors Analysis of Common Stock
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Daxor Corporation NASDAQ:DXR | 55.35K | 1.3% | 0.8% | 0.4% | |
 Adicet Bio, Inc. NASDAQ:ACET | 10.00K | 35.7% | 20.1% | -28.7% | |
 MiNK Therapeutics, Inc. NASDAQ:INKT | 48.00 | -48.2% | -32.2% | N/A | |
 Spectral AI, Inc. NASDAQ:MDAI | 3.00K | 14.5% | -53.3% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 538.87B | 5816.0% | 1150.2% | 333.9% | |
 Pulmonx Corporation NASDAQ:LUNG | 42.00K | 2.5% | 2.6% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 73.33K | 34.6% | 21.5% | 19.3% | |
 CervoMed Inc. NASDAQ:CRVO | 8.70K | 15.3% | 33.7% | -1.7% | |
 Great Elm Group, Inc. NASDAQ:GEG | 25.00K | -5.9% | -0.8% | 10.8% | |
 XBiotech Inc. NASDAQ:XBIT | 276.73M | 0.7% | 1.1% | 1.3% | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 32.00K | -27.5% | -11.5% | N/A |
Daxor Corporation Fair Value Envelope
Related Guides
Continue your DXR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.